Abbate R, Gori AM, Farsi A, Attanasio M, Pepe G. Monitoring of low-molecular-weight heparins in cardiovas- cular disease. Am J Cardiol. 1998;82(5B):33L-36L. 130. Francis CW, Pellegrini VD Jr, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Com- parison of warfarin and dalteparin. J Bone Joint Surg Am. 1997;79(9):1365-1372. 131. Samama MM, Poller L. Contemporary laboratory moni- toring of low molecular weight heparins. Clin Lab Med. 1995;15(1):119-123. 132. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Iden- ti cation of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molec- ular weight heparin. Blood. 1991;78(9):2337-2343. 133. Bates SM, Greer IA, Middeldorp S, Veenstra D, Prabulos A-M, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2)(suppl):e691S-e736S. 134. Bara L, Leizorovicz A, Picolet H, et al. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in postsurgical patients treated with either Logiparin or unfrac- tionated heparin. Thromb Res. 1992;65(4-5):641-650. 135. Prandoni P, Lensing AW, B ller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intrave- nous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339(8791):441-445. 136. Walenga JM, Hoppensteadt D, Fareed J. Laboratory mon- itoring of the clinical effects of low molecular weight hepa- rins. Thromb Res. 1991;14:49-62. 137. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN; Fragmin-Study Group. Adjusted versus xed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;71(6):698-702. 138. 